Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: While ketamine has been increasingly studied for treatment resistant depression (TRD), the impact of sex differences on treatment outcomes has not been well studied. The objective was to ascertain whether there were differences in response to a single administration of ketamine for TRD between men and women, and between pre- and post-menopausal women. Methods: A randomized, double-blind, placebo-controlled trial (N=99; N=50 male; N=49 female) was conducted to investigate the efficacy of intravenous ketamine versus active placebo as augmentation of antidepressant therapy for TRD. Patients were assigned to one of five arms; one-time administration of ketamine of varying doses (i.e., 0.1, 0.2, 0.5, and 1.0 mg/kg), and one group receiving active placebo (intravenous midazolam). A priori-planned analyses were conducted to compare responses between women and men, as well pre- vs. postmenopausal women. Results: Analyses demonstrated no significant differences between women and men in terms of treatment response (F(1,80)=0.06, p=0.80). There were no significant differences in the frequency of adverse effects (AEs) reported by those assigned to ketamine treatment groups (p>0.21 for all AEs reported more than once), although women reported more headaches (12% vs. 6%, p=0.30) and nausea (10% vs. 6%, p=0.47). In comparing pre- vs. postmenopausal women, no differences in efficacy were observed (F(1,76)=0.36, p=0.55). Conclusions: Results do not support differential efficacy or tolerability of ketamine for the treatment of TRD between women and men, nor based on menopause status among women. However, larger trials with these a priori aims are needed to confirm these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 2×
“Ketamine is a dissociative anesthetic and an antagonist of N-methyl-d-aspartate receptors (NMDAr) (Duman et al., 2016; Sanacora et al., 2017; Tundo et al., 2015; Wilkinson et al., 2018).”
BackgroundSelf-citationBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 3×
“[PubMed: 20830664] Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM, 1998 Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS).”
MethodWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Self-citationFava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Self-citationThe use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Sex differences in the antidepressant-like effects of ketamine
Carrier, N., & Kabbaj, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.12.009 · Cited by 251 · cited 4×
“However, they are in contrast with other studies in both humans and animals that suggest sex differences (Carrier and Kabbaj, 2013; Celia Moreira Borella et al., 2016; Coyle and Laws, 2015; Franceschelli et al., 2015; Guo et al., 2016; Sarkar and Kabbaj, 2016; van den Buuse et al., 2015; Wright et al., 2017).”
BackgroundResultInfluentialSex differences in glutamate receptor gene expression in major depression and suicide
Gray, A. L., Hyde, T. M., Deep-Soboslay, A., Kleinman, J. E., & Sodhi, M. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.91 · Cited by 250
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165 · cited 2×
“In a pooled analysis of four studies assessing ketamine infusions as a treatment for MDD or bipolar depression, investigators did not find that sex was predictive of depression outcomes (Niciu et al., 2014).”
BackgroundResultGender differences in subjective discontinuation symptoms associated with ketamine use
Chen, W.-Y., Huang, M.-C., & Lin, S.-K. (2014) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-9-39 · Cited by 87 · cited 2×
“, 2015), increased withdrawal symptoms, and subjectively reported cognitive symptoms (Chen et al., 2014).”
Background
Cited by
GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions
Gerhard, D. M., Pothula, S., Liu, R.-J., Wu, M., Li, X.-Y., Girgenti, M. J., Taylor, S. R., Duman, C. H., Delpire, E., Picciotto, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130808 · Cited by 345
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“In addition, both preclinical and clinical studies have demonstrated sex differences in the antidepressant efficacy and side effect profile of ketamine and its metabolites, further underscoring its pharmacokinetic complexity [19, 20].”
BackgroundConley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
O’Brien, B., Lijffijt, M., Wells, A., Swann, A. C., & Mathew, S. J. (2019) · Pharmaceuticals · doi:10.3390/ph12030133 · Cited by 33
“Although women had higher QIDS-SR scores than men irrespective of treatment, we found no evidence of different treatment responses between men and women, extending the lack of gender effects reported in controlled clinical trials using single dose infusion [26] to a clinical setting.”
BackgroundSelf-citation(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Metadata
- Authors
- Freeman, M. P., Papakostas, G. I., Hoeppner, B., Mazzone, E., Judge, H., Cusin, C., Mathew, S., Sanacora, G., Iosifescu, D., DeBattista, C., Trivedi, M. H., & Fava, M.
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 110
- Pages
- 166-171
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W2908836405
- Cited by
- 69
- References
- 10
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. https://app.cochat.ai/papers/10.1016/j.jpsychires.2019.01.010
- The paper
- Freeman, M. P., Papakostas, G. I., Hoeppner, B., Mazzone, E., Judge, H., Cusin, C., Mathew, S., Sanacora, G., Iosifescu, D., DeBattista, C., Trivedi, M. H., & Fava, M. (2019). Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2019.01.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.